Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 9/20 | 0.65 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.59 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.58 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10459242 | 0.95 | ADORA2A (0.59) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 | |
| SCHEMBL10459214 | 0.94 | ADORA2A (0.58) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 | |
| SCHEMBL10459485 | 0.94 | ADORA3 (0.57) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 | |
| SCHEMBL10458796 | 0.94 | ADORA3 (0.60) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 | |
| SCHEMBL10456423 | 0.94 | ADORA2A (0.62) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 | |
| SCHEMBL10459363 | 0.92 | ADORA2A (0.64) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 | |
| SCHEMBL14532795 | 0.91 | ADORA2A (0.65) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 | |
| SCHEMBL13385561 | 0.91 | ADORA2A (0.65) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 | |
| SCHEMBL10459403 | 0.91 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 | |
| SCHEMBL14393652 | 0.91 | ADORA3 (0.58) | ADORA3ADORA2AADORA1ADORA2BHSP90B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8222228-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | FOREST LABORATORIES HOLDINGS LIMITED (BM) | 2012-07-17 | — | — | US | disclosed |
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | PGXHEALTH, LLC (US) | 2011-04-21 | — | — | US | disclosed |
| US-7888329-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGXHEALTH, LLC (US) | 2011-02-15 | — | — | US | disclosed |
| US-7589076-B2 | Substituted aryl piperidinylalkynyladenosines as A2AR agonists | PGX HEALTH, LLC (US) | 2009-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110091385-A1 | SUBSTITUTED ARYL PIPERIDINYLALKYNYLADENOSINES AS A2AR AGONISTS | ADORA2A, ADORA1, ADORA3 | ADORA3 3/4885ADORA2A 1/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.